Losartan's re-prescription & re-dispensing are imminent

It is predicted that the items collected and the work guidelines will be finalized this week

Claims from hospitals and pharmacies → The NHIS delivered to companies → Deposits to nursing institutions for pharmaceutical companies

While the government's follow-up measures based on the results of Losartan impurity detection are expected to be announced this week, attention is being paid to the work guidelines for re-prescription and re-prevention.

 

Items with problems with all manufacturing numbers are expected to be re-prescribed and re-manufactured, and items with problems with some manufacturing numbers will be exchanged.

 

Earlier, the MOHW and the MFDS held two meetings with the Korean Medical Association and the KMA, the KHA, and the KSHP.

 

In addition, meetings with the KPBMA and the KPDA were held and plans were made for follow-up measures such as cost settlement.

 

According to the government's discussions with organizations so far, exchanges are likely to take the same measures as the detection of Azido impurities in September.

 

If exchanged at a pharmacy according to patient needs, it will be changed to a normal lot number, and 110% of the drug price will be added to the drug price to settle by the pharmaceutical company.

 

Since the Korean Pharmaceutical Association already has a related system and the exchange rate was low earlier, it is expected that there will be few problems with the exchange again this time.

 

In the case of re-prescription, it will be a method in which the pharmaceutical company that received the claim details is reimbursed to the nursing institution every month.

 

When a hospital or clinic re-prescribes the remaining amount of the patient's possession, the pharmacy proceeds with the claim through the existing claim program.

 

It plans to assign a specific code to claims for re-dispensing.

 

The HIRA and the NHIS check and deliver them to pharmaceutical companies every month.

 

Since then, pharmaceutical companies have to pay hospitals, pharmacies, etc.

 

within a set period (about a week).

 

Detailed guidelines for the payment of expenses to nursing institutions of pharmaceutical companies are expected to be guided by the government through a confirmed guide.

 

If mixed preparation is performed with powdered medicine, it is expected that drugs other than those subject to recovery will be exchanged.

 

The size of the impurity detection items finally announced by the migrant government is expected to determine the impact on pharmacies.